Win Advisors Inc. Acquires Shares of 11,701 DexCom, Inc. (NASDAQ:DXCM)

Win Advisors Inc. acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 11,701 shares of the medical device company's stock, valued at approximately $799,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Private Trust Co. NA increased its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of DexCom during the 4th quarter worth $33,000. TD Private Client Wealth LLC increased its stake in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Barclays increased their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. The Goldman Sachs Group initiated coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $98.50.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the firm's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the transaction, the executive vice president now directly owns 95,602 shares of the company's stock, valued at $8,057,336.56. The trade was a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,724 shares of company stock worth $2,157,034 in the last ninety days. Insiders own 0.32% of the company's stock.

DexCom Stock Performance

NASDAQ DXCM opened at $79.84 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The firm has a market capitalization of $31.31 billion, a price-to-earnings ratio of 59.58, a P/E/G ratio of 1.71 and a beta of 1.46. The company's fifty day moving average is $80.33 and its two-hundred day moving average is $79.41. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.32 earnings per share. Equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.